Skip to main content
BEAM logo

Beam Therapeutics Inc.

BEAMNASDAQHealthcareBiotechnology

$24.73Today:- (-)1Y −4.11%

As of Oct 15, 2026 close

Market cap
$2.58B
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$20.23$38.26
Volume (live)
-
Avg. volume (3M)
1.97M

Beam Therapeutics (BEAM) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Beam Therapeutics used $345.10M of cash in operating activities and spent $14.95M on capital expenditures. That left free cash flow of −$360.05M.

Beam Therapeutics Cash Flow Statement Analysis

Values in billions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Beam Therapeutics Inc. (BEAM) - Annual data in billions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating Activities
Net Income-0.08-0.38-0.13-0.29-0.37-0.19-0.08-0.12-0.01
Depreciation & Amortization0.020.020.020.010.010.000.000.000.00
Deferred Income Tax0.000.000.000.000.000.060.000.010.00
Stock Based Compensation0.090.120.100.080.040.020.010.010.00
Change in Working Capital-0.13-0.11-0.120.250.110.01-0.010.010.00
Change in Accounts Receivable0.000.000.000.30-0.300.000.000.000.00
Change in Inventory0.000.000.00-0.300.000.000.000.000.00
Change in Accounts Payable0.010.00-0.010.000.000.000.000.000.00
Change in Other Working Capital0.020.01-0.020.25-0.280.01-0.010.010.00
Other Operating Activities0.020.01-0.02-0.040.140.010.010.070.00
Net Cash from Operating Activities-0.35-0.35-0.150.02-0.07-0.10-0.07-0.020.00
Investing Activities
Capital Expenditures-0.01-0.01-0.03-0.05-0.05-0.02-0.01-0.010.00
Acquisitions0.000.000.000.410.000.080.000.000.00
Purchases of Investments-1.21-0.49-0.98-1.62-0.78-0.28-0.130.000.00
Sales/Maturities of Investments0.850.681.091.200.530.200.080.000.00
Other Investing Activities0.250.000.00-0.410.00-0.080.000.000.00
Net Cash from Investing Activities-0.120.190.07-0.46-0.29-0.10-0.07-0.010.00
Financing Activities
Debt Repayment0.000.000.000.000.000.000.010.000.00
Common Stock Issued0.470.010.280.110.770.320.000.180.00
Other Financing Activities0.000.000.000.01-0.010.000.040.180.00
Net Cash from Financing Activities0.480.010.280.110.760.320.040.180.00
Summary
Net Change in Cash0.01-0.150.20-0.330.400.13-0.100.150.00
Cash at Beginning of Period0.290.440.250.570.180.050.150.000.00
Cash at End of Period0.300.290.440.250.570.180.050.150.00
Free Cash Flow-0.36-0.36-0.18-0.03-0.11-0.11-0.08-0.030.00
Supplemental Disclosures
Interest Paid-0.000.000.000.000.00---

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Beam Therapeutics Cash Flow

What is Beam Therapeutics's free cash flow?

Beam Therapeutics had negative free cash flow of $360.05M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$345.10M minus $14.95M of capital expenditures.

How much does Beam Therapeutics spend on capital expenditures?

Beam Therapeutics spent $14.95M on capital expenditures in fiscal 2025, compared with $8.95M a year earlier.

Does Beam Therapeutics pay dividends or buy back shares?

Beam Therapeutics's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition